



Network Notification

Notice Date: July 17, 2026
To: Senior Care Options and One Care Providers
From: Commonwealth Care Alliance® (CCA)
Subject: August 2026 Updates to CCA's Medical Specialty Drug Policies
Effective Date: August 17, 2026

Summary

Effective August 17, 2026, Commonwealth Care Alliance® (CCA) is updating select Medical Specialty Drug Policies for our Senior Care Options (SCO) and One Care plans. To help you prepare, this communication outlines the policies that are changing and where to find additional information. We encourage you to review the "Summary of Changes" section within each policy to understand any updates that may affect the care of your CCA-covered patients. Medical Specialty Drug Policies can be accessed here: [Medical Necessity Guidelines | Commonwealth Care Alliance MA](#)

Bimonthly Policy Updates

Every other month you will receive a consolidated network notification summarizing all recent medical specialty drug policy changes. This helps you stay informed and up to date with minimal effort.

How to Use This Notification:

- Review the list of updated policies located here: [Medical Necessity Guidelines | Commonwealth Care Alliance MA](#)
- Note the effective date and the specific plans impacted by each policy.

Medical Specialty Drug Policy Updates

Policy	New or Revised
Alzheimer's Disease – Amyloid Beta-Directed Antibodies – Kisunla UM Medical	Revised
Alzheimer's Disease – Amyloid Beta-Directed Antibodies – Leqembi Intravenous UM Medical	Revised
Amyloidosis – Amvuttra UM Medical	Revised

Policy	New or Revised
Bone Modifiers – Denosumab Products (Prolia) UM Medical	Revised
Bone Modifiers – Denosumab Products (Xgeva) UM Medical	Revised
Bone Modifiers – Evenity UM Medical	Revised
Bone Modifiers – Ibandronate Intravenous UM Medical	Revised
Bone Modifiers – Zoledronic Acid (Reclast) UM Medical	Revised
Bone Modifiers – Zoledronic Acid (Zometa) UM Medical	Revised
Diabetes – Tzield UM Medical	Revised
Enzyme Replacement Therapy – Aldurazyme UM Medical	Revised
Enzyme Replacement Therapy – Avlayah UM Medical	New
Enzyme Replacement Therapy – Elaprase UM Medical	Revised
Enzyme Replacement Therapy – Fabrazyme UM Medical	Revised
Enzyme Replacement Therapy – Kanuma UM Medical	Revised
Enzyme Replacement Therapy – Lamzede UM Medical	Revised
Enzyme Replacement Therapy – Loargys UM Medical	New
Enzyme Replacement Therapy – Mepsevii UM Medical	Revised
Enzyme Replacement Therapy – Naglazyme UM Medical	Revised
Enzyme Replacement Therapy – Vimizim UM Medical	Revised
Gaucher Disease – Enzyme Replacement Therapy – Elelyso UM Medical	Revised
Gaucher Disease – Enzyme Replacement Therapy – Vpriv UM Medical	Revised
Gaucher Disease – Enzyme Replacement Therapy Cerezyme UM Medical	Revised
Gonadotropin-Releasing Hormone Agonists – Implants UM Medical	Revised
Homozygous Familial Hypercholesterolemia – Evkeeza UM Medical	Revised
Human Immunodeficiency Virus – Trogarzo UM Medical	Revised
Hyperlipidemia – PCSK9 Inhibitors – Leqvio UM Medical	Revised
Immune Disorders – Gene Therapy – Waskyra UM Medical	New
Immune Globulin – Intravenous UM Medical	Revised
Immunologicals – Cinqair UM Medical	Revised

Policy	New or Revised
Immunologicals – Fasenra UM Medical	Revised
Immunologicals – Xolair UM Medical	Revised
Inflammatory Conditions – Cimzia UM Medical	Revised
Inflammatory Conditions – Entyvio Intravenous UM Medical	Revised
Inflammatory Conditions – Orencia Intravenous UM Medical	Revised
Inflammatory Conditions – Spevigo Intravenous UM Medical	Revised
Inflammatory Conditions – Tocilizumab Intravenous Products UM Medical	Revised
Inflammatory Conditions – Ustekinumab Intravenous Products UM Medical	Revised
Lupus – Benlysta Intravenous UM Medical	Revised
Lupus – Saphnelo UM Medical	Revised
Metabolic Disorders – Incivree UM Medical	Revised
Metabolic Disorders – Nulibry UM Medical	Revised
Metabolic Disorders – Primary Hyperoxaluria – Rivfloza UM Medical	Revised
Migraine – Calcitonin Gene-Related Peptide Inhibitors – Vyepti UM Medical	Revised
Muscular Dystrophy – Exondys 51 UM Medical	Revised
Muscular Dystrophy – Gene Therapy – Elevidys UM Medical	Revised
Neurology – Brineura UM Medical	Revised
Neurology – Edaravone IV UM Medical	Revised
Neurology – Gene Therapy – Kebilidi UM Medical	Revised
Neurology – Qalsody UM Medical	Revised
Oncology (Injectable – Antibody-Drug Conjugate –c-Met) – Emrelis UM Medical	Revised
Oncology (Injectable – Asparaginase) – Rylaze UM Medical	Revised
Oncology (Injectable – Bispecific – BCMA-Directed) – Tecvayli UM Medical	Revised
Oncology (Injectable – CAR-T) – Abecma UM Medical	Revised
Oncology (Injectable – CAR-T) – Carvykti UM Medical	Revised
Oncology (Injectable – CAR-T) – Kymriah UM Medical	Revised
Oncology (Injectable – CAR-T) – Yescarta UM Medical	Revised

Policy	New or Revised
Oncology (Injectable – CD38-Directed Cytolytic Antibody) – Darzalex Faspro UM Medical	Revised
Oncology (Injectable – CD38-Directed Cytolytic Antibody) – Darzalex Intravenous UM Medical	Revised
Oncology (Injectable – CD38-Directed Cytolytic Antibody) – Sarclisa UM Medical	Revised
Oncology (Injectable – CTLA-4 Antibody) – Imjudo UM Medical	Revised
Oncology (Injectable – EGFR- and MET-Directed Antibody) – Rybrevant Faspro UM Medical	Revised
Oncology (Injectable – EGFR- and MET-Directed Antibody) – Rybrevant Intravenous UM Medical	Revised
Oncology (Injectable – HER2 Antagonist) – Herceptin Hylecta UM Medical	Revised
Oncology (Injectable – Microtubule Inhibitor) – Halaven UM Medical	Revised
Oncology (Injectable – Microtubule Inhibitor) – Jevtana UM Medical	Revised
Oncology (Injectable – Programmed Death Receptor-1) – Opdivo Intravenous UM Medical	Revised
Oncology (Injectable – Programmed Death Receptor-1) – Zynyz UM Medical	Revised
Oncology (Injectable – Programmed Death-Ligand 1) – Tecentriq Hybreza UM Medical	Revised
Oncology (Injectable – Programmed Death-Ligand 1) – Tecentriq UM Medical	Revised
Oncology (Injectable – Proteasome Inhibitor) – Kyprolis UM Medical	Revised
Oncology (Injectable) – Adcetris UM Medical	Revised
Oncology (Injectable) – Cosela UM Medical	Revised
Oncology (Injectable) – Empliciti UM Medical	Revised
Oncology (Injectable) – Imlygic UM Medical	Revised
Oncology (Injectable) – Pluvicto UM Medical	Revised
Oncology (Injectable) – Provenge UM Medical	Revised
Oncology (Intravesical) – Adstiladrin UM Medical	Revised
Oncology (Intravesical) – Anktiva UM Medical	Revised
Ophthalmology – Gene Therapy – Encelto UM Medical	Revised

Policy	New or Revised
Ophthalmology – Gene Therapy – Luxturna UM Medical	Revised
Ophthalmology – Izervay UM Medical	Revised
Ophthalmology – Syfovre UM Medical	Revised
Ophthalmology – Vascular Endothelial Growth Factor Inhibitors – Vabysmo UM Medical	Revised
Otolaryngology – Gene Therapy – Otarmeni UM Medical	New
Parkinson’s Disease – Onapgo UM Medical	Revised
Parkinson’s Disease – Vyalev UM Medical	Revised
Pulmonary Arterial Hypertension – Epoprostenol Products UM Medical	Revised
Pulmonary Arterial Hypertension – Treprostinil Injection UM Medical	Revised
Somatostatin Analogs – Lanreotide Products UM Medical	Revised
Somatostatin Analogs – Lutathera UM Medical	Revised
Somatostatin Analogs – Signifor LAR UM Medical	Revised
Spinal Muscular Atrophy – Spinraza UM Medical	Revised
Thrombocytopenia – Nplate UM Medical	Revised

Questions?

For more information, please contact CCA Provider Services at 1-866-420-9332. Hours of availability are 8:00 a.m. to 5:00 p.m. Monday through Wednesday and Friday, and on Thursdays from 8:30 a.m. to 5:00 p.m., Eastern Time (ET).

Thank you for your partnership and for the care you provide for our members.